Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | GRM1 | Q13255 | 6/20 | 0.36 |
| ▸ | GRM5 | P41594 | 4/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL926212 | 0.78 | HSD17B10 (0.43) | HSD17B10GAAKDM4EALDH1A1HPGD | |
| SCHEMBL924275 | 0.77 | GAA (0.40) | HSD17B10GAAKDM4EALDH1A1HPGD | |
| SCHEMBL923798 | 0.75 | HSD17B10 (0.39) | HSD17B10GAAKDM4EALDH1A1HPGD | |
| SCHEMBL925096 | 0.74 | KDM4E (0.41) | HSD17B10GAAKDM4EALDH1A1HPGD | |
| SCHEMBL924196 | 0.74 | ALDH1A1 (0.54) | HSD17B10GAAKDM4EALDH1A1HPGD | |
| SCHEMBL25352885 | 0.74 | HSD17B10 (0.48) | HSD17B10GAAKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL27612290 | 0.74 | NOTUM (0.39) | HSD17B10GAAKDM4EALDH1A1HPGD | |
| SCHEMBL924407 | 0.71 | BACE1 (0.47) | HSD17B10GAAKDM4EALDH1A1HPGD | |
| SCHEMBL924171 | 0.70 | HSD17B10 (0.42) | HSD17B10GAAKDM4EALDH1A1HPGD | |
| SCHEMBL924527 | 0.69 | HSD17B10 (0.49) | HSD17B10GAAKDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163766-B2 | Beta-secretase modulators and methods of use | AMGEN INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20110118250-A1 | BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-7872009-B2 | Beta-Secretase modulators and methods of use | AMGEN INC. (US) | 2011-01-18 | — | — | US | disclosed |
| US-20070185103-A1 | Beta-secretase modulators and methods of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118250-A1 | BETA-SECRETASE MODULATORS AND METHODS OF USE | BACE1, BACE2, APP | HSD17B10 1966/4885GAA 44/4885KDM4E 1391/4885 |
| US-20070185103-A1 | Beta-secretase modulators and methods of use | BACE1, BACE2, APP | HSD17B10 1966/4885GAA 44/4885KDM4E 1391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.